A National Network of Depression Centers task group outlined four recurring challenges in psychedelic clinical trials: treatment nonresponse, expectancy effects and functional unblinding, post-session psychological difficulties, and contagion effects between participants. In one Phase 2b psilocybin study referenced in the paper, suicidal ideation occurred in about 1.9% of certain dose groups, underscoring the need for tight screening and monitoring. The authors argue that rigorous participant selection, structured safety protocols, and clearer trial design are essential if psychedelic therapies are to scale responsibly beyond research settings.